CA2553943C - Oxidative reductive potential water solution, processes for producing same and methods of using the same - Google Patents
Oxidative reductive potential water solution, processes for producing same and methods of using the same Download PDFInfo
- Publication number
- CA2553943C CA2553943C CA2553943A CA2553943A CA2553943C CA 2553943 C CA2553943 C CA 2553943C CA 2553943 A CA2553943 A CA 2553943A CA 2553943 A CA2553943 A CA 2553943A CA 2553943 C CA2553943 C CA 2553943C
- Authority
- CA
- Canada
- Prior art keywords
- solution
- formulation
- water solution
- orp water
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 438
- 238000000034 method Methods 0.000 title claims abstract description 99
- 230000001590 oxidative effect Effects 0.000 title claims abstract description 43
- 230000008569 process Effects 0.000 title claims abstract description 18
- 230000002829 reductive effect Effects 0.000 title claims description 47
- 230000009467 reduction Effects 0.000 claims abstract description 37
- 230000001771 impaired effect Effects 0.000 claims abstract description 23
- 230000000249 desinfective effect Effects 0.000 claims abstract description 7
- 230000002924 anti-infective effect Effects 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 411
- 239000000203 mixture Substances 0.000 claims description 149
- 238000009472 formulation Methods 0.000 claims description 125
- 239000012266 salt solution Substances 0.000 claims description 74
- 210000001519 tissue Anatomy 0.000 claims description 58
- 239000000460 chlorine Substances 0.000 claims description 54
- 229910052801 chlorine Inorganic materials 0.000 claims description 52
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 50
- 238000002360 preparation method Methods 0.000 claims description 48
- 239000002562 thickening agent Substances 0.000 claims description 40
- 238000011282 treatment Methods 0.000 claims description 33
- 241000894007 species Species 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- -1 hypochlorite ions Chemical class 0.000 claims description 28
- 208000015181 infectious disease Diseases 0.000 claims description 28
- 241000894006 Bacteria Species 0.000 claims description 27
- 238000005868 electrolysis reaction Methods 0.000 claims description 27
- 238000001356 surgical procedure Methods 0.000 claims description 27
- 241000700605 Viruses Species 0.000 claims description 26
- 230000003472 neutralizing effect Effects 0.000 claims description 25
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 claims description 24
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 claims description 23
- 244000005700 microbiome Species 0.000 claims description 22
- 239000000499 gel Substances 0.000 claims description 21
- 241000233866 Fungi Species 0.000 claims description 20
- 210000004379 membrane Anatomy 0.000 claims description 16
- 239000012528 membrane Substances 0.000 claims description 16
- 238000011200 topical administration Methods 0.000 claims description 16
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 15
- 239000000645 desinfectant Substances 0.000 claims description 14
- 241000588724 Escherichia coli Species 0.000 claims description 13
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 claims description 13
- 239000004155 Chlorine dioxide Substances 0.000 claims description 12
- 241000191967 Staphylococcus aureus Species 0.000 claims description 12
- 235000019398 chlorine dioxide Nutrition 0.000 claims description 12
- 239000000725 suspension Substances 0.000 claims description 12
- 239000005708 Sodium hypochlorite Substances 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 10
- 206010009137 Chronic sinusitis Diseases 0.000 claims description 10
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 10
- 230000000241 respiratory effect Effects 0.000 claims description 10
- 201000009890 sinusitis Diseases 0.000 claims description 10
- 206010020751 Hypersensitivity Diseases 0.000 claims description 9
- 239000007921 spray Substances 0.000 claims description 9
- 208000025865 Ulcer Diseases 0.000 claims description 8
- 238000012387 aerosolization Methods 0.000 claims description 8
- 238000000889 atomisation Methods 0.000 claims description 8
- 238000002663 nebulization Methods 0.000 claims description 8
- 241000222122 Candida albicans Species 0.000 claims description 7
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 7
- 229940095731 candida albicans Drugs 0.000 claims description 7
- 231100000397 ulcer Toxicity 0.000 claims description 7
- 230000029663 wound healing Effects 0.000 claims description 7
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Inorganic materials Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 5
- 238000005299 abrasion Methods 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 244000063299 Bacillus subtilis Species 0.000 claims description 4
- 241000709661 Enterovirus Species 0.000 claims description 4
- 210000000214 mouth Anatomy 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 241000701161 unidentified adenovirus Species 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 3
- 208000010201 Exanthema Diseases 0.000 claims description 3
- 208000002847 Surgical Wound Diseases 0.000 claims description 3
- 229910001919 chlorite Inorganic materials 0.000 claims description 3
- 229910052619 chlorite group Inorganic materials 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 201000005884 exanthem Diseases 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 210000004400 mucous membrane Anatomy 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 206010037844 rash Diseases 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 2
- 210000000683 abdominal cavity Anatomy 0.000 claims description 2
- 208000030961 allergic reaction Diseases 0.000 claims description 2
- 238000002266 amputation Methods 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 210000004262 dental pulp cavity Anatomy 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000007943 implant Substances 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 210000000115 thoracic cavity Anatomy 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 2
- 230000003647 oxidation Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 43
- 239000007844 bleaching agent Substances 0.000 description 41
- 239000000758 substrate Substances 0.000 description 39
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 36
- 206010052428 Wound Diseases 0.000 description 30
- 208000027418 Wounds and injury Diseases 0.000 description 28
- 238000006722 reduction reaction Methods 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 26
- 229920000642 polymer Polymers 0.000 description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 230000000694 effects Effects 0.000 description 19
- 239000000463 material Substances 0.000 description 18
- 229920002125 Sokalan® Polymers 0.000 description 17
- 239000003242 anti bacterial agent Substances 0.000 description 16
- 229940088710 antibiotic agent Drugs 0.000 description 16
- 201000007100 Pharyngitis Diseases 0.000 description 15
- 238000004140 cleaning Methods 0.000 description 15
- 238000004659 sterilization and disinfection Methods 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000007789 gas Substances 0.000 description 14
- 150000002500 ions Chemical class 0.000 description 14
- 238000002156 mixing Methods 0.000 description 13
- 239000004744 fabric Substances 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 239000013566 allergen Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 10
- 230000002411 adverse Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000003014 ion exchange membrane Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 9
- 239000000443 aerosol Substances 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 229910001415 sodium ion Inorganic materials 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 230000007794 irritation Effects 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 150000002978 peroxides Chemical class 0.000 description 7
- 229920003023 plastic Polymers 0.000 description 7
- 239000004033 plastic Substances 0.000 description 7
- 241000194017 Streptococcus Species 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- 208000016150 acute pharyngitis Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000002421 anti-septic effect Effects 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 5
- 206010072369 Pharyngeal exudate Diseases 0.000 description 5
- 241000589516 Pseudomonas Species 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 206010001093 acute tonsillitis Diseases 0.000 description 5
- 230000007815 allergy Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000004061 bleaching Methods 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 210000002850 nasal mucosa Anatomy 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 4
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 4
- 208000008960 Diabetic foot Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 238000011888 autopsy Methods 0.000 description 4
- 230000000721 bacterilogical effect Effects 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 229920001903 high density polyethylene Polymers 0.000 description 4
- 239000004700 high-density polyethylene Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 230000033116 oxidation-reduction process Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 206010044008 tonsillitis Diseases 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 3
- 206010001076 Acute sinusitis Diseases 0.000 description 3
- 206010001889 Alveolitis Diseases 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000013626 chemical specie Substances 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 3
- UQSQSQZYBQSBJZ-UHFFFAOYSA-N fluorosulfonic acid Chemical compound OS(F)(=O)=O UQSQSQZYBQSBJZ-UHFFFAOYSA-N 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000006199 nebulizer Substances 0.000 description 3
- 239000004745 nonwoven fabric Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 231100000057 systemic toxicity Toxicity 0.000 description 3
- 239000004753 textile Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 231100000041 toxicology testing Toxicity 0.000 description 3
- 230000003253 viricidal effect Effects 0.000 description 3
- RFIMISVNSAUMBU-UHFFFAOYSA-N 2-(hydroxymethyl)-2-(prop-2-enoxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC=C RFIMISVNSAUMBU-UHFFFAOYSA-N 0.000 description 2
- QNGVNLMMEQUVQK-UHFFFAOYSA-N 4-n,4-n-diethylbenzene-1,4-diamine Chemical compound CCN(CC)C1=CC=C(N)C=C1 QNGVNLMMEQUVQK-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- RUPBZQFQVRMKDG-UHFFFAOYSA-M Didecyldimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC RUPBZQFQVRMKDG-UHFFFAOYSA-M 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001430197 Mollicutes Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000000592 Nasal Polyps Diseases 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 208000005141 Otitis Diseases 0.000 description 2
- 206010034839 Pharyngitis streptococcal Diseases 0.000 description 2
- 206010035039 Piloerection Diseases 0.000 description 2
- 206010067268 Post procedural infection Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 206010044013 Tonsillitis streptococcal Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 231100000921 acute inhalation toxicity Toxicity 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000021120 animal protein Nutrition 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 235000011116 calcium hydroxide Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000002800 charge carrier Substances 0.000 description 2
- 229960002626 clarithromycin Drugs 0.000 description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 208000019258 ear infection Diseases 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229920002313 fluoropolymer Polymers 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002070 germicidal effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000007952 growth promoter Substances 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229920001684 low density polyethylene Polymers 0.000 description 2
- 239000004702 low-density polyethylene Substances 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 206010033072 otitis externa Diseases 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000005371 pilomotor reflex Effects 0.000 description 2
- 235000021118 plant-derived protein Nutrition 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 239000002964 rayon Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 239000012209 synthetic fiber Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 206010047470 viral myocarditis Diseases 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- CGLVZFOCZLHKOH-UHFFFAOYSA-N 8,18-dichloro-5,15-diethyl-5,15-dihydrodiindolo(3,2-b:3',2'-m)triphenodioxazine Chemical compound CCN1C2=CC=CC=C2C2=C1C=C1OC3=C(Cl)C4=NC(C=C5C6=CC=CC=C6N(C5=C5)CC)=C5OC4=C(Cl)C3=NC1=C2 CGLVZFOCZLHKOH-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical class [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical class ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 208000031973 Conjunctivitis infective Diseases 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 102100031051 Cysteine and glycine-rich protein 1 Human genes 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010060803 Diabetic foot infection Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000922020 Homo sapiens Cysteine and glycine-rich protein 1 Proteins 0.000 description 1
- 101001019104 Homo sapiens Mediator of RNA polymerase II transcription subunit 14 Proteins 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000003892 Kartagener syndrome Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 229920010126 Linear Low Density Polyethylene (LLDPE) Polymers 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 241001191345 Osa Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010057009 Pharyngeal erythema Diseases 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920005830 Polyurethane Foam Polymers 0.000 description 1
- 206010036303 Post streptococcal glomerulonephritis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 229920001131 Pulp (paper) Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NSOXQYCFHDMMGV-UHFFFAOYSA-N Tetrakis(2-hydroxypropyl)ethylenediamine Chemical compound CC(O)CN(CC(C)O)CCN(CC(C)O)CC(C)O NSOXQYCFHDMMGV-UHFFFAOYSA-N 0.000 description 1
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 229920001938 Vegetable gum Polymers 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000001028 acute contagious conjunctivitis Diseases 0.000 description 1
- 231100000109 acute inhalation LD50 Toxicity 0.000 description 1
- 230000008578 acute process Effects 0.000 description 1
- 201000005638 acute proliferative glomerulonephritis Diseases 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 210000002534 adenoid Anatomy 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000011366 aggressive therapy Methods 0.000 description 1
- 239000013572 airborne allergen Substances 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229940086737 allyl sucrose Drugs 0.000 description 1
- NLKOSPLGBAHDND-UHFFFAOYSA-N aluminum chromium(3+) cobalt(2+) oxygen(2-) Chemical compound [O--].[O--].[O--].[O--].[Al+3].[Cr+3].[Co++] NLKOSPLGBAHDND-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000011902 cervical lymphadenopathy Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- MAYPHUUCLRDEAZ-UHFFFAOYSA-N chlorine peroxide Inorganic materials ClOOCl MAYPHUUCLRDEAZ-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000007682 dermal toxicity Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000000804 electron spin resonance spectroscopy Methods 0.000 description 1
- 238000013129 endoscopic sinus surgery Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 150000004680 hydrogen peroxides Chemical class 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 231100000016 inhalation toxicity Toxicity 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 238000004900 laundering Methods 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- LWXVCCOAQYNXNX-UHFFFAOYSA-N lithium hypochlorite Chemical compound [Li+].Cl[O-] LWXVCCOAQYNXNX-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- YZQBYALVHAANGI-UHFFFAOYSA-N magnesium;dihypochlorite Chemical compound [Mg+2].Cl[O-].Cl[O-] YZQBYALVHAANGI-UHFFFAOYSA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920005646 polycarboxylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000011496 polyurethane foam Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 201000009266 primary ciliary dyskinesia Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001869 rapid Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000000934 spermatocidal agent Substances 0.000 description 1
- 230000003330 sporicidal effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000583 toxicological profile Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical group OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000012873 virucide Substances 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
- A61L2/186—Peroxide solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
- C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
- C02F1/46104—Devices therefor; Their operating or servicing
- C02F1/4618—Devices therefor; Their operating or servicing for producing "ionised" acidic or basic water
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/24—Medical instruments, e.g. endoscopes, catheters, sharps
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
- C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
- C02F1/467—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction
- C02F1/4672—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction by electrooxydation
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/72—Treatment of water, waste water, or sewage by oxidation
- C02F1/722—Oxidation by peroxides
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/72—Treatment of water, waste water, or sewage by oxidation
- C02F1/76—Treatment of water, waste water, or sewage by oxidation with halogens or compounds of halogens
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
- C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
- C02F1/46104—Devices therefor; Their operating or servicing
- C02F1/4618—Devices therefor; Their operating or servicing for producing "ionised" acidic or basic water
- C02F2001/46195—Devices therefor; Their operating or servicing for producing "ionised" acidic or basic water characterised by the oxidation reduction potential [ORP]
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2103/00—Nature of the water, waste water, sewage or sludge to be treated
- C02F2103/02—Non-contaminated water, e.g. for industrial water supply
- C02F2103/026—Treating water for medical or cosmetic purposes
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2201/00—Apparatus for treatment of water, waste water or sewage
- C02F2201/46—Apparatus for electrochemical processes
- C02F2201/461—Electrolysis apparatus
- C02F2201/46105—Details relating to the electrolytic devices
- C02F2201/46115—Electrolytic cell with membranes or diaphragms
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2209/00—Controlling or monitoring parameters in water treatment
- C02F2209/04—Oxidation reduction potential [ORP]
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2209/00—Controlling or monitoring parameters in water treatment
- C02F2209/06—Controlling or monitoring parameters in water treatment pH
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2209/00—Controlling or monitoring parameters in water treatment
- C02F2209/40—Liquid flow rate
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2303/00—Specific treatment goals
- C02F2303/04—Disinfection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Hydrology & Water Resources (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Electrochemistry (AREA)
- Cardiology (AREA)
- Environmental & Geological Engineering (AREA)
- Water Supply & Treatment (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Water Treatment By Electricity Or Magnetism (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53358303P | 2003-12-30 | 2003-12-30 | |
| US60/533,583 | 2003-12-30 | ||
| US10/862,092 US20050139808A1 (en) | 2003-12-30 | 2004-06-04 | Oxidative reductive potential water solution and process for producing same |
| US10/862,092 | 2004-06-04 | ||
| US10/916,278 | 2004-08-11 | ||
| US10/916,566 US9168318B2 (en) | 2003-12-30 | 2004-08-11 | Oxidative reductive potential water solution and methods of using the same |
| US10/916,278 US20050196462A1 (en) | 2003-12-30 | 2004-08-11 | Topical formulation containing oxidative reductive potential water solution and method for using same |
| US10/916,566 | 2004-08-11 | ||
| PCT/US2004/043961 WO2005065383A2 (en) | 2003-12-30 | 2004-12-30 | Oxidative reductive potential water solution, processes for producing same and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2553943A1 CA2553943A1 (en) | 2005-07-21 |
| CA2553943C true CA2553943C (en) | 2014-02-11 |
Family
ID=34753897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2553943A Expired - Fee Related CA2553943C (en) | 2003-12-30 | 2004-12-30 | Oxidative reductive potential water solution, processes for producing same and methods of using the same |
Country Status (7)
| Country | Link |
|---|---|
| EP (2) | EP3205358A1 (enExample) |
| JP (1) | JP5528657B2 (enExample) |
| KR (1) | KR101249639B1 (enExample) |
| AU (1) | AU2004311432A1 (enExample) |
| CA (1) | CA2553943C (enExample) |
| MX (1) | MXPA05009960A (enExample) |
| WO (1) | WO2005065383A2 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5140218B2 (ja) | 2001-09-14 | 2013-02-06 | 有限会社コヒーレントテクノロジー | 表面洗浄・表面処理に適した帯電アノード水の製造用電解槽及びその製造法、並びに使用方法 |
| ATE535262T1 (de) | 2001-12-05 | 2011-12-15 | Oculus Innovative Sciences Inc | Verfahren und vorrichtung zur erzeugung von wasser mit negativem und positivem redoxpotential (orp) |
| US9168318B2 (en) | 2003-12-30 | 2015-10-27 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and methods of using the same |
| BRPI0609711B8 (pt) | 2005-03-23 | 2021-05-25 | Oculus Innovative Sciences Inc | uso de uma solução aquosa com potencial redutivo oxidativo (orp) |
| BRPI0610901B1 (pt) | 2005-05-02 | 2019-04-16 | Oculus Innovative Sciences, Inc. | Uso de uma solução aquosa de potencial oxi-redutivo (orp). |
| GB2429152A (en) * | 2005-08-19 | 2007-02-21 | Forum Bioscience Holdings Ltd | Electrochemically activated water for use as a virucide |
| JP5060032B2 (ja) * | 2005-09-12 | 2012-10-31 | 株式会社ヒロマイト | 還元性水性組成物 |
| PT1945576E (pt) | 2005-10-28 | 2013-01-16 | Apr Nanotechnologies S A | Dispositivo que compreende um eléctrodo com nanorevestimento para a preparação de uma solução aquosa de estabilidade elevada e método de fabrico desta solução aquosa |
| AU2007205861B2 (en) * | 2006-01-20 | 2013-05-09 | Oculus Innovative Sciences, Inc. | Methods of treating or preventing sinusitis with oxidative reductive potential water solution |
| CN101405011A (zh) * | 2006-01-20 | 2009-04-08 | 奥古露丝创新科学公司 | 使用氧化还原电位水溶液治疗或预防窦炎的方法 |
| GB2442519A (en) * | 2006-10-02 | 2008-04-09 | Forum Bioscience Holdings Ltd | Wound treatment compositions |
| JP5313874B2 (ja) * | 2007-03-22 | 2013-10-09 | 大幸薬品株式会社 | アレルゲン不活性化剤 |
| US8709495B2 (en) | 2007-04-25 | 2014-04-29 | Apr Nanotechnologies S.A. | Highly stable electrolytic water with reduced NMR half line width |
| CA2702796A1 (en) * | 2007-10-23 | 2009-04-30 | Novozymes A/S | Methods for killing spores and disinfecting or sterilizing devices |
| US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
| SK50172008A3 (sk) * | 2008-02-20 | 2010-03-08 | Ľubomír Vozár | Ekologicky neškodlivý dezinfekčný prostriedok |
| EP2376093B1 (en) * | 2008-12-22 | 2020-07-15 | Sonoma Pharmaceuticals, Inc. | Treating or preventing biofilm associated infections with free available chlorine water |
| US10342825B2 (en) | 2009-06-15 | 2019-07-09 | Sonoma Pharmaceuticals, Inc. | Solution containing hypochlorous acid and methods of using same |
| ES2549913T3 (es) | 2009-06-17 | 2015-11-03 | Apr Nanotechnologies S.A. | Métodos de tratamiento de trastornos oculares externos usando agua ácida de alto ORP y composiciones de la misma |
| GB0912865D0 (en) * | 2009-07-23 | 2009-08-26 | Applied Chemistry Ltd | Endoscope decontamination system |
| US10265341B2 (en) | 2009-07-30 | 2019-04-23 | Sonoma Pharmaceuticals, Inc. | Hydrogel formulation comprising oxidative reductive potential water |
| JP5831673B2 (ja) * | 2010-01-22 | 2015-12-09 | 東洋製罐株式会社 | 空間表面の殺菌方法 |
| JP2011167665A (ja) * | 2010-02-22 | 2011-09-01 | Meiko Shoji Kk | アルカリイオン水スプレー装置 |
| CN102939130A (zh) | 2010-04-14 | 2013-02-20 | 海波流动有限公司 | 制备稀释消毒剂溶液的设备 |
| US8641874B2 (en) * | 2010-12-09 | 2014-02-04 | Rayne Guest | Compact closed-loop electrolyzing process and apparatus |
| US20120156307A1 (en) * | 2010-12-16 | 2012-06-21 | Apr Nanotechnologies S.A. | Medical uses of nanoclustered water |
| US8882972B2 (en) | 2011-07-19 | 2014-11-11 | Ecolab Usa Inc | Support of ion exchange membranes |
| US11357794B2 (en) | 2012-02-17 | 2022-06-14 | Wiab Wafer Innovation Ab | Preparations for controlled-release of hypochlorous acid |
| US11364263B2 (en) | 2012-02-17 | 2022-06-21 | Wiab Wafer Innovation Ab | Compositions and methods for aerodigestive treatment |
| US12115185B2 (en) | 2012-02-17 | 2024-10-15 | Wiab Water Innovation Ab | Compositions of hypochlorous acid and methods of manufacture thereof |
| US11364262B2 (en) | 2012-02-17 | 2022-06-21 | Wiab Water Innovation Ab | Acetic acid and hypochlorous acid compositions for treatment of skin trauma |
| ES2966295T3 (es) | 2012-02-17 | 2024-04-19 | Wiab Water Innovation Ab | Composiciones de ácido hipocloroso (HOCl) y métodos de fabricación de las mismas |
| US11484549B2 (en) | 2012-02-17 | 2022-11-01 | Wiab Water Innovation Ab | Compositions and methods for treating biofilms without inducing antimicrobial resistance |
| US11452741B2 (en) | 2012-02-17 | 2022-09-27 | Wiab Water Innovation Ab | Compositions and methods for treating transient biofilms |
| US11672825B2 (en) | 2012-02-17 | 2023-06-13 | Wiab Water Innovation Ab | Acetic acid and hypochlorous acid compositions for treatment of biofilms and wound care |
| US10675299B2 (en) * | 2012-02-17 | 2020-06-09 | Wiab Water Innovation Ab | Hand disinfectant |
| US11478507B2 (en) | 2012-02-17 | 2022-10-25 | Wiab Water Innovation Ab | Compositions and methods for treating biofilms |
| WO2013134327A1 (en) * | 2012-03-06 | 2013-09-12 | Raymat Materials, Inc. | Disinfectant solution |
| EP2999341B1 (en) | 2013-05-22 | 2018-11-28 | Sonoma Pharmaceuticals, Inc. | Stabilized hypochlorous acid solution and use thereof |
| AU2014343506C1 (en) | 2013-10-29 | 2023-06-01 | Hypo-Stream Limited | Anti-inflammatory solution comprising sodium hypochlorite |
| EP3475231A4 (en) * | 2016-06-22 | 2020-07-29 | Briotech, Inc. | INACTIVATION OF HIGHLY RESISTANT INFECTIOUS PROTEIN AND MICROBES WITH BUFFER-FREE HYPOHALEUS ACID COMPOSITIONS |
| EP3518998A1 (en) * | 2016-09-30 | 2019-08-07 | Eastern Technologies, Inc. | Oxidative reductive potential water solution, processes for producing same and methods of using the same |
| CN108926492A (zh) * | 2017-05-25 | 2018-12-04 | 北京甲护生物科技有限公司 | 一种酸性氧化电位水消毒湿巾的制备方法 |
| SG11202006664UA (en) | 2018-01-14 | 2020-08-28 | Collidion Inc | Compositions, kits, methods and uses for cleaning, disinfecting, sterilizing and/or treating |
| US11116791B2 (en) * | 2018-04-25 | 2021-09-14 | Rdg Holdings, Inc. | Compositions and methods for the treatment of cystic fibrosis |
| FR3089520B1 (fr) * | 2018-12-07 | 2021-09-17 | Commissariat Energie Atomique | Pâte de decontamination et procede de decontamination d’un substrat en un materiau solide utilisant cette pâte |
| IT202000013996A1 (it) * | 2020-06-25 | 2021-12-25 | Mitsa S R L | Metodo ed apparato per la purificazione e sterilizzazione dell’acqua |
| CN112076215A (zh) * | 2020-08-18 | 2020-12-15 | 珠海市索利达医疗器械有限公司 | 一种改善生殖道微生态的抗菌组合物及其应用 |
| MX2023002291A (es) * | 2020-08-25 | 2023-06-15 | Collidion Inc | Métodos y usos en la producción de composiciones estables que comprenden peróxidos y especies de cloro libre disponible. |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3499844A (en) * | 1967-08-21 | 1970-03-10 | Fmc Corp | Method of preparing an aqueous hydrogen peroxide gel |
| US4236992A (en) * | 1979-08-06 | 1980-12-02 | Themy Constantinos D | High voltage electrolytic cell |
| US4574084A (en) * | 1983-02-25 | 1986-03-04 | Peter Berger | Process for the preparation of a modified aqueous chlorite solution, the solution prepared by this process and the use thereof |
| US4670254A (en) * | 1983-12-09 | 1987-06-02 | Toko Yakuhin Industry Co., Ltd. | Gel preparations for topical application of diclofenac sodium |
| US4615937A (en) | 1985-09-05 | 1986-10-07 | The James River Corporation | Antimicrobially active, non-woven web used in a wet wiper |
| US4666621A (en) | 1986-04-02 | 1987-05-19 | Sterling Drug Inc. | Pre-moistened, streak-free, lint-free hard surface wiping article |
| US4781974A (en) | 1986-04-23 | 1988-11-01 | James River Corporation | Antimicrobially active wet wiper |
| US5388571A (en) | 1987-07-17 | 1995-02-14 | Roberts; Josephine A. | Positive-pressure ventilator system with controlled access for nebulizer component servicing |
| FI82808C (fi) | 1987-12-31 | 1991-04-25 | Etelae Haemeen Keuhkovammayhdi | Ultraljudfinfoerdelningsanordning. |
| DE3929411A1 (de) * | 1988-09-22 | 1990-03-29 | Siegfried Natterer | Pharmazeutische zubereitung sowie verfahren zu ihrer herstellung |
| JPH03176022A (ja) * | 1989-12-04 | 1991-07-31 | Olympus Optical Co Ltd | 内視鏡用洗浄消毒装置 |
| US5622848A (en) | 1990-05-23 | 1997-04-22 | Medical Discoveries, Inc. | Electrically hydrolyzed salines as microbiocides for in vitro treatment of contaminated fluids containing blood |
| US5334383A (en) | 1990-05-23 | 1994-08-02 | Medical Discoveries, Inc. | Electrically hydrolyzed salines as in vivo microbicides for treatment of cardiomyopathy and multiple sclerosis |
| DE69218901T2 (de) | 1991-12-10 | 1997-07-17 | Tdk Corp | Ultraschallzerstäuber |
| US5287847A (en) | 1992-07-24 | 1994-02-22 | Vortran Medical Technology, Inc. | Universal nebulizer |
| GB9227020D0 (en) * | 1992-12-24 | 1993-02-17 | Solvay Interox Ltd | Microbicidual compositions |
| DK0706352T3 (da) | 1993-06-29 | 2002-07-15 | Ponwell Entpr Ltd | Dispenser |
| FI971966A0 (fi) | 1994-11-09 | 1997-05-07 | Procter & Gamble | Vesi lipidissä -emulsiolla käsiteltyjä pehmeitä puhdistuspapereita |
| FR2740335B1 (fr) * | 1995-10-26 | 1997-12-19 | Oreal | Utilisation de sel de lanthanide, de lithium, d'etain, de zinc, de manganese ou d'yttrium comme antagoniste de substance p |
| JPH09157173A (ja) * | 1995-11-02 | 1997-06-17 | Asahi Glass Eng Kk | ヒドロキシラジカル含有酸性水 |
| TR199802167T2 (xx) | 1996-04-30 | 2001-06-21 | The Procter & Gamble Company | Bir y�ksek dahili faz ters-em�lsiyon ile i�lenmi� temizlik malzemeleri. |
| US6028018A (en) | 1996-07-24 | 2000-02-22 | Kimberly-Clark Worldwide, Inc. | Wet wipes with improved softness |
| US5908707A (en) | 1996-12-05 | 1999-06-01 | The Procter & Gamble Company | Cleaning articles comprising a high internal phase inverse emulsion and a carrier with controlled absorbency |
| CN1293805C (zh) * | 1997-10-10 | 2007-01-10 | 纯生物科学公司 | 消毒剂及其制造方法 |
| JPH11269686A (ja) * | 1998-03-18 | 1999-10-05 | Permelec Electrode Ltd | 過酸化水素の製造方法及び過酸化水素製造用電解槽 |
| JP2000015263A (ja) * | 1998-07-07 | 2000-01-18 | Kinosui Kenkyusho:Kk | 電解アルカリ殺菌水およびその製造装置 |
| US7163349B2 (en) | 1998-11-09 | 2007-01-16 | The Procter & Gamble Company | Combined cleaning pad and cleaning implement |
| SE9902627D0 (sv) | 1999-07-08 | 1999-07-08 | Siemens Elema Ab | Medical nebulizer |
| GB2355190B (en) * | 1999-08-23 | 2004-07-28 | Sterilox Medical | Improvements in or relating to sterilising preparations |
| JP2001139477A (ja) | 1999-11-17 | 2001-05-22 | Coherent Technology:Kk | 創傷部位の組織細胞増殖促進液 |
| US6340663B1 (en) | 1999-11-24 | 2002-01-22 | The Clorox Company | Cleaning wipes |
| US6387383B1 (en) * | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
| JP2002145787A (ja) * | 2000-11-02 | 2002-05-22 | Kanebo Ltd | 外用剤 |
| US6586385B1 (en) | 2001-11-13 | 2003-07-01 | Colgate-Palmolive Co. | Cleaning wipe |
| US6624135B2 (en) | 2001-11-26 | 2003-09-23 | S.C. Johnson & Son, Inc. | Cleaning sheet |
| ATE535262T1 (de) | 2001-12-05 | 2011-12-15 | Oculus Innovative Sciences Inc | Verfahren und vorrichtung zur erzeugung von wasser mit negativem und positivem redoxpotential (orp) |
| JP2005058848A (ja) * | 2003-08-08 | 2005-03-10 | Spring:Kk | 洗浄・消毒・創傷治癒に用いられる水の製造方法、その製造装置、及び洗浄・消毒・創傷治癒に用いられる水 |
-
2004
- 2004-12-30 MX MXPA05009960A patent/MXPA05009960A/es active IP Right Grant
- 2004-12-30 JP JP2006547576A patent/JP5528657B2/ja not_active Expired - Lifetime
- 2004-12-30 EP EP17155148.4A patent/EP3205358A1/en not_active Withdrawn
- 2004-12-30 CA CA2553943A patent/CA2553943C/en not_active Expired - Fee Related
- 2004-12-30 WO PCT/US2004/043961 patent/WO2005065383A2/en not_active Ceased
- 2004-12-30 KR KR1020067015435A patent/KR101249639B1/ko not_active Expired - Fee Related
- 2004-12-30 AU AU2004311432A patent/AU2004311432A1/en not_active Abandoned
- 2004-12-30 EP EP04815950A patent/EP1702161A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007517064A (ja) | 2007-06-28 |
| CA2553943A1 (en) | 2005-07-21 |
| EP1702161A2 (en) | 2006-09-20 |
| KR101249639B1 (ko) | 2013-04-01 |
| WO2005065383A2 (en) | 2005-07-21 |
| AU2004311432A1 (en) | 2005-07-21 |
| MXPA05009960A (es) | 2006-05-25 |
| EP3205358A1 (en) | 2017-08-16 |
| JP5528657B2 (ja) | 2014-06-25 |
| KR20070015123A (ko) | 2007-02-01 |
| WO2005065383A3 (en) | 2006-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2553943C (en) | Oxidative reductive potential water solution, processes for producing same and methods of using the same | |
| AU2011200390B2 (en) | Oxidative reductive potential water solution, processes for producing same and methods of using the same | |
| US10016455B2 (en) | Method of preventing or treating influenza with oxidative reductive potential water solution | |
| US8840873B2 (en) | Method of treating second and third degree burns using oxidative reductive potential water solution | |
| AU2007205861B2 (en) | Methods of treating or preventing sinusitis with oxidative reductive potential water solution | |
| US9498548B2 (en) | Method of using oxidative reductive potential water solution in dental applications | |
| CN101163492B (zh) | 利用氧化还原电位水溶液治疗2度和3度烧伤的方法 | |
| AU2012241151B2 (en) | Method of using oxidative reductive potential water solution in dental applications | |
| HK1096372B (en) | Oxidative reductive potential water solution, processes for producing same and methods of using the same | |
| HK1096372A1 (en) | Oxidative reductive potential water solution, processes for producing same and methods of using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20210831 |
|
| MKLA | Lapsed |
Effective date: 20191230 |